INFO & CONTACTS:  +39 02 2390 1

A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents With or Without Pembrolizumab in Participants with PD-1/L1 Refractory Locally Advanced or Metastatic Urothelial Carcinoma (KEYMAKER-U04): Substudy 04A

Phase: Phase I-II clinical trials

Principal Investigator: Dott.ssa Verzoni Elena

Main Facility: Oncologia Medica Genitourinaria

Drug: MK-3120 + pembro

Pathologies: Urological cancers (kidney, bladder, urinary tract, others)

The total number of investigational treatment arms will depend on the number of investigational agents evaluated. This study protocol will include a minimum of 1 investigational treatment arms. Refer to Appendix 6, Section 10.6.1. Arm A includes participants treated with MK-2140 and Arm B includes participants treated with MK-3120 plus pembrolizumab. 

Last update: 17/04/2026

Subscribe to the newsletter

Sign up for our newsletter to stay informed about news, events, and updates from the Institute

Subscribe